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ABSTRACT  
AIMS: Reflux symptoms are highly prevalent and non-specific hence, in the absence of 
alarm symptoms, endoscopy referral decisions are challenging. This study evaluated 
whether a non-endoscopic Cytosponge could detect benign oesophageal pathologies and 
thus have future potential in triaging patients with persistent symptoms. 
METHODS AND RESULTS:  Two complementary cohorts were recruited: 1) Patients with 
reflux symptoms and no prior endoscopy (n=409); 2) Patients with reflux symptoms referred 
for endoscopy (n=411). All patients were investigated using the Cytosponge and endoscopy. 
Significant epithelial inflammation was present in 130 (16%) Cytosponge samples of which 
32 had ulcer slough. Candida and significant inflammation was detected in a further 22 
(2.3%) cases; epithelial infiltration with   >15 eosinophils/hpf reflecting possible eosinophilic 
oesophagitis (EOE) in five (0.6%); and viral inclusions suggestive of herpes oesophagitis in 
one (0.1%). No significant pathology was detected in the majority, 662 (81%), of Cytosponge 
samples.  
Cytosponge and endoscopy findings were in agreement in 574 (70%) cases, in most 
discordant cases, 165 (67%), one investigation showed mild inflammation whilst the other 
was negative; with an additional 22 (8.9%) differing on the inflammation extent. Eighteen 
cases with severe inflammation, six with candida and two with EOE were detected only at 
endoscopy; whilst 18 with candida and significant inflammation, 13 with ulcer slough, one 
probable EOE, and one viral oesophagitis were identified on the Cytosponge only.  
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CONCLUSIONS: The Cytosponge detects a range of benign oesophageal pathologies, and 
therefore has potential clinical utility in the triaging of patients with troublesome reflux 
symptoms. This warrants further investigation. 
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INTRODUCTION  
Gastro-oesophageal reflux symptoms are highly prevalent in the westernised world, 
affecting 10-44% of the general population, and continue to increase in incidence (1). They 
are the most common gastrointestinal symptoms resulting in physician office visits in the US 
and accrue the highest annual costs (2, 3). US and UK guidelines suggest that patients 
reporting classical symptoms of dyspepsia, heartburn and/or regurgitation should be 
managed as presumptive gastrointestinal reflux disease (GORD) with advice on life-style 
modifications, reviewing any contributory drugs, and a trial of proton pump inhibitors (PPI) 
(4, 5). If symptoms return on initial discontinuation of PPI therapy, it is recommended to 
restart the drug and to tailor the dosing schedule to maximise symptom control (4, 5). In the 
majority of cases this would be expected to fully-control symptoms, however 17-32% of 
patients in a Primary Care setting remain symptomatic (6). Currently it is recommended that 
this group requires further optimisation of medical therapy followed by a referral to 
specialist services with consideration of an upper gastro-intestinal endoscopy (OGD) to 
identify patients with erosive esophagitis, Barrett’s oesophagus or other benign diagnosis 
requiring further management and/or disease surveillance (4, 5, 7, 8).  
Erosive oesophagitis is the most common positive OGD finding in patients with reflux 
symptoms (9), identified in 12-34% (10, 11). However reflux symptoms may be secondary to 
alternative pathologies which are non-responsive to PPIs and therefore require alternative 
management (12). The most prevalent is candida oesophagitis identified in 2.3-3.8% of all 
OGDs (13-15). When symptomatic, it presents predominantly with reflux symptoms (14), 
and requires treatment with anti-fungal medication. Eosinophilic oesophagitis (EOE) is a 
condition of uncertain aetiology which is increasing in incidence (16). Acute dysphagia is the 
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classical presentation (17), however EOE is identified in 1% of patients who are investigated 
for reflux symptoms and requires management with a trial of PPI, topical or systemic 
steroids, and/or dietary elimination (18, 19).  
It is estimated however, that at least two-thirds of OGDs in patients with reflux symptoms 
will not reveal any diagnostic pathology. An OGD requires patients to be referred to 
secondary care, to undergo a relatively invasive procedure, and has associated costs of 
approximately $685 or £400 per out-patient investigation (2, 20). Previous studies have 
demonstrated a non-endoscopic cell sampling method, the Cytosponge, to be a safe and 
well-tolerated method to sample the oesophageal lining which can be undertaken in a 
primary-care setting by nurse practitioners (21-23). The device yields a combination of 
single cells and micro-biopsies which quantitatively exceeds that achieved by a biopy 
(Supplementary Figure 1). Compared to an OGD, it offers a cost-effective method to 
diagnose Barrett’s oesophagus in high-risk patients (24) with a high sensitivity and specificity 
when combined with TFF3 immunohistochemistry (23, 25), and has also demonstrated 
utility in monitoring disease activity in patients with EOE (26).  
The aim of this study was to explore in symptomatic patients with no prior oesophageal 
diagnosis, the ability of the Cytosponge to detect benign oesophageal pathology aside from 
Barrett’s oesophagus.  
 
METHODS 
Study cohort 
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The study group comprised two complementary cohorts, patients enrolled in the BEST study 
(21) and the control group from the BEST2 study (23). To summarise, the BEST cohort was 
identified from a Primary Care setting, and had received acid-suppression medication for at 
least three consecutive months in the five years prior to being enrolled in the study. These 
patients were not considered to require an OGD by their Primary Care Physician. Patients 
were excluded if they were known to have Barrett’s oesophagus or if they had had an OGD 
in the twelve months prior to enrolment. The BEST2 control group were patients who had 
been referred for an OGD to investigate dyspepsia and/or reflux symptoms refractory to 
medical therapy. Patients with a prior diagnosis of Barrett’s oesophagus were excluded. 
The UK Medical Health Regulatory Agency issued a letter of no objection for the use of the 
Cytosponge (Medical Research Council, London, UK) in both studies. The BEST and BEST2 
studies were approved by Cambridge Regional Ethics Committee (LREC 06/Q0108/272) and 
the East of England–Cambridge Central Research Ethics Committee (No: 10/H0308/71) 
respectively. BEST2 was registered in the UK Clinical Research Network Study Portfolio 
(9461). Each patient provided written informed consent. 
Cytosponge administration and processing 
The Cytosponge was administered by a research nurse and following retrieval was stored at 
4oC in SurePath preservative (TriPath Imaging, Burlington, North Carolina, US) before being 
transferred to the laboratory for processing to paraffin blocks (21, 23). One haematoxylin 
and eosin (H&E) stained slide was generated per sample and all cases were reviewed by at 
least two independent observers (MoD & PLS), one of whom (MoD) is a specialist 
cytopathologist and gastrointestinal pathologist. Any features suggestive of benign 
pathology were recorded. In a subset of cases (n=7) where both Candida and significant 
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inflammation was present on the H&E stained slide, a periodic acid-Schiff (PAS) stain was 
undertaken to improve diagnostic certainty. 
Patients then underwent an OGD with biopsies taken where clinically indicated according to 
usual clinical care. All the endoscopists in the study were Consultant-level with a particular 
interest in oesophageal disease and followed a study protocol. Endoscopic findings were 
categorised based on the endoscopy report and supplemented by histopathology findings 
when biopsies were undertaken. Mild oesophagitis was defined as Los Angeles oesophagitis 
grades A or B, or inflammation only identified on a biopsy, whilst severe oesophagitis was 
defined as the presence of Los Angeles grades C or D erosions (4), and/or ulceration. This 
was an observational study and no therapy was initiated as a result of Cytosponge findings; 
patient management was adjusted as per current recommendations based on the 
endoscopic findings. 
The sensitivity and specificity of the Cytosponge as a screening tool for Barrett’s oesophagus 
and associated dysplasia has been reported previously (23), therefore cases where Barrett’s 
oesophagus was identified using the Cytosponge and/or OGD were excluded (n=94), unless 
an additional significant benign pathology was also present (n=9).  
Statistical Analysis 
Statistics for continuous variables were expressed as medians and interquartile ranges. The 
Mann-Whitney test was used to compare continuous variables between groups, and a Chi-
square test was used to compare counts between categorical variables. 
 
RESULTS  
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A total of 820 patients met the inclusion criteria for the study, 409 patients from BEST and 
411 from BEST2. The demographic data is summarised in Table 1. The BEST group reported 
less well controlled symptoms compared with the BEST2 cohort, were older and more likely 
to have a high BMI and/or waist:hip ratio. 
Cytosponge findings 
A range of benign oesophageal pathologies were identified using the Cytosponge. 662/820 
(81%) of Cytosponge samples were considered to be within normal limits (Figure 1 a,b), 
including occasional samples containing Aspergillus species, a recognised commensal in 
tonsillar tissue (Figure 1 c,d). In the majority of cases, only occasional acute and chronic 
inflammatory cells were present, usually separate from epithelial fragments, and therefore 
were deemed not to be clinically significant. However in a subgroup of patients, 98/820 
(12%), abundant acute and chronic inflammatory cells were seen to permeate the epithelial 
fragments (Figure 1, e,f), or to be present in dense clusters separate from the epithelial 
fragments. In both situations, this was felt to represent clinically significant inflammation.  In 
32 (3.9%) additional cases, dense aggregates of predominantly acute inflammatory cells 
were observed with abundant associated fibrin (Figure 1, g,h), and interpreted as sampling 
from the surface of an ulcer.  
Fungal spores and/or pseudo-hyphae with an appearance consistent with Candida species 
were identified in 35/820 (4.3%) cases. Since Candida is a known commensal within the 
oropharynx, its presence was only judged to be potentially pathogenic in 22/820 (2.7%) 
patients where significant inflammation was also present (Figure 1, i,l).  
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In 5/820 (0.6%) cases eosinophils were seen to infiltrate between epithelial cells with a 
density of >15 eosinophils per high power field, and with microabscess formation in some 
cases (Figure 1, m,n). Therefore these samples met multiple histological criteria used for the 
diagnosis of EOE on biopsy (18), and were designated possible EOE. 
Viral nuclear inclusions, representing herpes oesophagitis, were present in a single case 
(Figure 1, o,p).  
 
Endoscopic findings and comparison with the Cytosponge 
In the majority of cases, 638/820 (78%), no significant pathology was identified at 
endoscopy. Oesophagitis was the most common pathology and present in 166/820 (20%) 
cases, the majority of which, 101/166 (61%), were Grade A oesophagitis with only 30/166 
(18%) having severe oesophagitis. Candida oesophagitis and EOE were identified in 10/820 
(1.2%) and 6/820 (0.7%) cases respectively.  
There was agreement between the findings on endoscopy and Cytosponge in 596/820 (73%) 
cases, with both showing no significant pathology in 541/820 (66%) (Table 2). Both 
investigations led to a diagnosis in some cases which was not corroborated by the other 
test. In 121/820 (15%) cases the Cytosponge was negative when a pathology was identified 
at endoscopy (Table 2). This was predominantly mild inflammation, 97/121 (80%), as well as 
18 cases (15%) with severe oesophagitis and 6 cases (5.0%) of candida oesophagitis. In 
97/820 (11%) cases the endoscopy was negative when the Cytosponge identified pathology 
(Table 2). The missed diagnoses at endoscopy were significant inflammation or ulceration in 
81/97 (84%) patients, candida with significant accompanying inflammation in 15/97 (15%), 
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and a single case with viral inclusions suggestive of herpes oesophagitis. In 80/97 (82%) 
cases where pathology was noted on the Cytosponge but not at endoscopy, no biopsy had 
been taken at endoscopy as it was not felt to be clinically indicated. In three cases mild 
atypia was noted on the Cytosponge sample however since significant inflammation related 
to reflux, Candida or EOE was also present, the significance is unclear and this may 
represent reactive changes. No squamous dysplasia was seen in the single case where a 
biopsy was also taken. 
In a further 6/820 (0.7%) cases, there was disagreement between the OGD and Cytosponge 
findings. In two cases the Cytosponge detected mild inflammation whilst the OGD suggested 
that this was due to EOE; and in four cases the OGD found mild oesophagitis whilst the 
Cytosponge examination suggested that this was secondary to candida oesophagitis (three 
cases) and EOE (one case). 
 
DISCUSSION  
This study has demonstrated the ability of a minimally invasive sampling device, the 
Cytosponge, to detect a broad range of benign oesophageal pathologies. This is a 
preliminary study, however it does suggest that this test has future potential for triaging and 
possibly even guiding the management of patients with reflux symptoms, and warrants 
further research to explore the clinical utility of such a strategy.  
The Cytosponge can be administered by a nurse practitioner in a primary-care or specialist 
clinic setting within a fifteen minute appointment. From the patient’s perspective this may 
be more convenient than an out-patient endoscopy and previous studies have shown that 
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most patients do not find the Cytosponge to be an unpleasant or anxiety provoking 
investigation, preferring it to endoscopy (21, 23). From a health-economics perspective, the 
Cytosponge is anticipated to be cheaper to deliver than an endoscopy, mainly because it 
does not require specialist services or equipment.  
In the majority of cases, 66%, both the Cytosponge and endoscopy showed no significant 
pathology. Alternative diagnoses to GORD were identified in 36 (4.4%) patients, when the 
findings from the OGD and Cytosponge are combined, consistent with previous findings (14, 
15, 19). The main diagnosis was Candida with significant associated inflammation, which 
was detected more than twice as frequently using the Cytosponge compared to an OGD. A 
PAS stain was also shown to be effective in highlighting Candida species on Cytosponge 
samples, and could be used selectively in future studies to increase the sensitivity of the 
Cytosponge to detect Candida in cases with severe inflammation and ulceration. The clinical 
significance of candida identified using the Cytosponge needs further study, however such 
patients could be treated by a short-course of anti-fungal therapy which is well tolerated 
and it is likely that such cases would not have symptom control with PPIs alone.  
The majority of patients with EOE present with dysphagia, and so would be referred directly 
for endoscopy (17), however a sub-set have predominantly reflux-type symptoms and the 
Cytosponge detected five cases of probable EOE in our study groups. Diagnostic criteria 
applied to biopsies, the presence of >15 eosinophils per high power field infiltrating the 
epithelium and/or the presence of eosinophilic micro-abscesses (18), are equally applicable 
to the Cytosponge samples due to the micro-biopsies that are obtained. A recent small 
study of patients with known EOE found that the Cytosponge had a sensitivity of 85% for 
identifying active disease (26). EOE is known to have a patchy distribution and may not be 
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visible endoscopically (12). A major advantage of the Cytosponge is that it samples the 
entire length of the oesophagus and so is less susceptible to sampling errors. However, 
eosinophils are frequently seen in biopsies from the distal oesophagus in reflux 
oesophagitis, hence to diagnose EOE at endoscopy, eosinophils should be present in 
biopsies taken from both the distal and proximal oesophagus (18). Therefore patients 
suspected of having EOE based on the Cytosponge findings would require endoscopic 
confirmation prior to starting treatment. 
The majority of missed diagnoses for both the sponge and endoscopy related to 
oesophagitis and/or ulceration. This disagreement is not unique to this setting since the 
scoring of oesophagitis and ulceration at endoscopy is known to have limited inter-observer 
agreement, k score 0.40-0.65 (27, 28). Furthermore the majority of medical adjustments to 
acid-suppression therapy are guided by patient symptoms, not by endoscopic findings (4), as 
patients can report severe symptoms in the absence of oesophagitis on endoscopy (27). 
A major challenge in the broader interpretation of this study is accurately calculating the 
specificity and sensitivity of the Cytosponge investigation (29). The endoscopy protocol 
reflected standard clinical practice, hence in the majority cases where pathology was 
identified on the Cytosponge but not macroscopically at endoscopy a biopsy was not taken, 
so it is not possible to confirm or refute the Cytosponge findings microscopically. 
Furthermore biopsies were not taken as standard to confirm the macroscopic impression of 
inflammation, therefore “false-negative” Cytosponge findings cannot be confirmed, 
particularly as concordance between endoscopists is known to be low for mild oesophagitis 
(27, 28).   
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Therefore given that the ability of the Cytosponge to detect benign oesophageal pathologies 
has now been established, future studies now need to be undertaken to accurately establish 
the sensitivity and specificity of this investigation compared to endoscopy and hence its 
potential clinical utility. For example, the Cytosponge may offer a means to triage patients 
with troublesome reflux symptoms, without alarm features, away from first-line endoscopic 
investigation. Patients in whom the Cytosponge demonstrates no significant pathology, 
epithelial inflammation without ulceration, or candida with associated inflammation, 
representing 95% of our cohort, could continue to be managed in primary care with 
adjustment of acid suppression therapy or anti-fungal medication as appropriate. Whilst 
those with evidence of ulceration, possible EOE or viral oesophagitis on the Cytosponge, in 
addition to those with troublesome, persistent or unexplained symptoms following a 
negative Cytosponge investigation would be referred for a diagnostic or follow-up 
endoscopy. An OGD would remain the investigation of choice for all patients presenting 
with alarm symptoms, or dyspepsia since the Cytosponge is not intended to be used to 
detect gastric pathology.  
To conclude, this research demonstrates the ability of the Cytosponge to detect benign 
oesophageal pathologies. Prospective studies are now required to explore its potential as a 
triage tool in patients with troublesome reflux symptoms. 
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FIGURE LEGENDS 
Figure 1: Representative H&E examples of each of the main diagnoses identified on the 
Cytosponge shown at x100 magnification with the boxed area also shown at x400 
magnification. (a,b) normal stratified squamous epithelium; (c,d) Aspergillus species 
representing normal colonisation of tonsillar tissue; (e,f) significant inflammation, indicated 
by inflammatory cells infiltrating between the epithelial cells; (g,h) ulceration comprising 
abundant inflammatory cells admixed with fibrin; (i-l) candida oesophagitis indicated by 
inflamed epithelium with fungal spores and pseudohyphae which can be highlighted using a 
periodic-acid Schiff (PAS) stain (k, l); (m, n) eosinophilic oesophagitis indicated by abundant 
eosinophils infiltrating between epithelial cells; (o,p) herpes oesophagitis shown by the 
present of an epithelial cell with nuclear inclusions. 
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TABLES 
 BEST BEST2 Combined  
Individuals 409 411 820  
Age – median (IQR) 62 (56-66)
 #
 56 (44-66) 60 (52-66)
 #
 p < 0.01 
Ethnicity – White Caucasian (%) 384 (94%)
$
 378 (92%) 762 (93%)
$
  p = 0.05 
M:F* 1.0:1.2
$
 1.0:1.3 1.0:1.3
$
 p = 0.65 
BMI - median (IQR) 29.0 (26.2-32.6)
 +
 26.8 (24.0-30.0)
 $
 28.0 (24.8-31.6)
 &
 p < 0.01 
Waist:Hip ratio – median (IQR) 0.91 (0.85-0.96) # 0.88 (0.83-0.94) # 0.89 (0.84-0.95)
%
 p < 0.01 
Symptom control (BEST)/ 
symptom frequency (BEST2) 
    
Well-controlled/never symptoms 25 (6.2%)
$
 55 (13%)^ 80 (9.9%)# p < 0.01 
Fairly well controlled /sometimes 85 (21%) 125 (31%) 210 (26%)  
Uncontrolled/often 111 (28%) 75 (18%) 186 (23%)  
Very poor or poor control/daily 181 (45%) 154 (38%) 335 (41%)  
 
Table 1: Demographics of the BEST and BEST2 study cohorts used in this study, and the two 
cohorts combined. * Sex ratio rounded to the nearest tenth. Data was unavailable for ^2, $7, 
+8, #9, &15 and %18 patients respectively.  
 Cytosponge Diagnosis  
  Negative Epith Inflam Ulcer Sig Candida EOE Viral Total 
Endoscopy 
diagnosis 
Negative 541 68 13 15 0 1 638 (78%) 
Mild inflam 97 21 15 2 1 0 136 (17%) 
Severe inflam 18 7 4 1 0 0 30 (3.7%) 
Candida 6 0 0 4 0 0 10 (1.2%) 
EOE 0 2 0 0 4 0 6 (0.7%) 
Viral 0 0 0 0 0 0 0 
 Total 662 (81%) 98 (12%) 32 (3.9%) 22(2.7%) 5 (0.6%) 1 (0.1%)  
 
Table 2: Comparison of the findings on OGD and using the Cytosponge. Cases with a shared 
diagnosis are shaded in blue, those where only the Cytosponge detected the dominant 
pathology are shaded green, and those when the main pathology was only identified by OGD 
are shaded red.  
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